Gilead's newly acquired CAR-T therapy Yescarta, developed by Kite Pharma, won FDA approval for certain B cell lymphomas on Oct. 18 and the company set its price $102,000 below Novartis's competing therapy Kymriah, which was approved in a small pediatric leukemia indication.
Gilead Sciences Inc. paid $11.9bn for Kite Pharma Inc. in a deal that closed earlier this month and will soon reap rewards from that long-awaited transaction following the Oct. 18 US FDA approval of Yescarta (axicabtagene ciloleucel), but its return on investment won't come at a market-leading price.
The autologous CD19-targeting chimeric antigen receptor T cell (CAR-T) therapy was approved for adults with relapsed or refractory large B-cell...
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
